

AMENDMENTS TO THE CLAIMS

Claims 1-62 (Canceled)

63. (Previously presented) A transgenic mouse whose genome comprises a disruption in an endogenous lymphoid specific GPCR gene, wherein where the disruption is homozygous, the transgenic mouse lacks production of functional lymphoid specific GPCR protein, and exhibits lymphocyte cellular infiltration of lung tissue.
64. (Previously presented) A transgenic mouse whose genome comprises a disruption in an endogenous lymphoid specific GPCR gene, wherein where the disruption is homozygous, the transgenic mouse lacks production of functional lymphoid specific GPCR protein, and exhibits lymphocyte cellular infiltration of pancreatic tissue.
65. (Previously presented) A transgenic mouse whose genome comprises a disruption in an endogenous lymphoid specific GPCR gene, wherein where the disruption is homozygous, the transgenic mouse lacks production of functional lymphoid specific GPCR protein, and exhibits lymphocyte cellular infiltration of liver tissue.
66. (Previously presented) A transgenic mouse whose genome comprises a disruption in an endogenous lymphoid specific GPCR gene, wherein where the disruption is homozygous, the transgenic mouse lacks production of functional lymphoid specific GPCR protein, and exhibits cellular infiltration of stomach tissue by at least one of the following types of cells: lymphocytes, granulocytes or plasma cells.
67. (Previously presented) A cell or tissue isolated from the transgenic mouse of claim 63, claim 64, claim 65, or claim 66.
68. (Previously presented) A transgenic mouse comprising a heterozygous disruption in an endogenous lymphoid specific GPCR gene, wherein, upon breeding, the disruption in a homozygous state inhibits production of functional lymphoid specific GPCR protein resulting in a transgenic mouse exhibiting at least one of the following phenotypes: lymphocyte infiltration of lung tissue, lymphocyte infiltration of pancreatic tissue, lymphocyte infiltration of liver tissue or lymphocyte, granulocyte or plasma cell infiltration of stomach tissue.
69. (Previously presented) A cell or tissue isolated from the transgenic mouse of claim 68.

70. (Currently amended) A method of producing a transgenic mouse comprising a disruption in an endogenous lymphoid specific GPCR gene, the method comprising:

- (a) introducing a targeting construct capable of disrupting the endogenous lymphoid specific GPCR gene into a murine embryonic stem cell;
 - (b) selecting for the murine embryonic stem cell that has undergone homologous recombination;
 - (c) introducing the murine embryonic stem cell selected for in step (b) into a mouse blastocyst;
 - (d) implanting the resulting blastocyst into a pseudopregnant mouse, wherein the resultant ~~pseudopregnant~~ mouse gives birth to a chimeric mouse; and
 - (e) breeding the chimeric mouse to produce the transgenic mouse,
- wherein where the disruption is homozygous, the transgenic mouse lacks production of functional lymphoid specific GPCR protein and exhibits at least one of the following phenotypes: lymphocyte infiltration of lung tissue, lymphocyte infiltration of pancreatic tissue, lymphocyte infiltration of liver tissue or lymphocyte, granulocyte or plasma cell infiltration of stomach tissue.

71. (Canceled)